Ligand Pharmaceuticals (LGND: Quote) partner GlaxoSmithKline (GSK: Quote) announced Monday morning that the FDA approved PROMACTA for the treatment of thrombocytopenia in patients with chronic hepatitis C.
Ligand Pharmaceuticals has spiked to the upside following a slightly delayed opening and is currently higher by 2.61 at $19.28. The stock is now challenging the highs of the year, trading at a 3-month high.
by RTT Staff Writer
For comments and feedback: email@example.com